CareDx (CDNA) vs Fortrea (FTRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
CareDx (CDNA) has outperformed Fortrea (FTRE) over the past year, gaining 329.7% versus a gain of 120.8%. CareDx is the larger company by market cap ($3.26 billion vs $1.96 billion), about 1.7 times the size. On valuation, Fortrea trades at a lower forward P/E (18.0x vs 48.9x for CareDx).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CDNA | FTRE |
|---|---|---|
| Share price | $63.04 | $20.56 |
| Market cap | $3.26B | $1.96B |
| 1-day change | -1.18% | -1.06% |
| YTD return | +234.61% | +19.19% |
| 1-year return | +329.72% | +120.84% |
| 5-year return | -11.21% | — |
| P/E ratio (TTM) | 30.60 | — |
| Forward P/E | 48.87 | 17.96 |
| EPS (TTM) | $2.06 | $-0.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $72.51 | $23.51 |
| 52-week low | $13.95 | $8.55 |
| Distance from 52-week high | -13.06% | -12.55% |
| Analyst consensus | buy | buy |
| Avg. price target upside | -6.68% | +1.31% |
| Average volume | 1.28M | 1.46M |
| Shares outstanding | 51.73M | 95.10M |
| Employees | 761 | 14,000 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CDNA has outperformed FTRE by 208.9 percentage points over the past year.
About CareDx
CDNA stock →CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally.
Health Care · Medical Specialities · 761 employees
About Fortrea
FTRE stock →Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services.
Health Care · Medical Specialities · 14,000 employees
CDNA vs FTRE FAQ
Which is bigger, CareDx or Fortrea?
CareDx (CDNA) is larger, with a market capitalization of $3.26B compared with $1.96B for Fortrea (FTRE).
Which stock has performed better over the past year, CDNA or FTRE?
CDNA returned +329.72% over the past 12 months, compared with +120.84% for FTRE (price return, excluding dividends). Past performance does not predict future results.
Are CareDx and Fortrea in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.